{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:37:37Z","timestamp":1784889457994,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Yaron Shemie"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.beem.2020.101411","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T03:38:33Z","timestamp":1583725113000},"page":"101411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?"],"prefix":"10.1016","volume":"34","author":[{"given":"Ruth","family":"Percik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2020.101411_bib1","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.beem.2020.101411_bib2","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.beem.2020.101411_bib3","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2020.101411_bib4","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2020.101411_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.juro.2016.02.3005","article-title":"Immunotherapy for the treatment of urothelial carcinoma","volume":"197","author":"Donin","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.beem.2020.101411_bib6","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2017.0156","article-title":"Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Spiess","year":"2017","journal-title":"J Natl Compr Cancer Netw: JNCCN"},{"key":"10.1016\/j.beem.2020.101411_bib7","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2020.101411_bib8","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2020.101411_bib9","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2020.101411_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beem.2020.101411_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2020.101411_bib12","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","article-title":"Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms","volume":"102","author":"Delivanis","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101411_bib13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beem.2020.101411_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2020.101411_bib15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.14310\/horm.2002.1754","article-title":"Endocrine sequelae of immune checkpoint inhibitors","volume":"16","author":"Ntali","year":"2017","journal-title":"Hormones"},{"key":"10.1016\/j.beem.2020.101411_bib16","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1530\/EJE-19-0169","article-title":"Management of endocrine disease: immune check point inhibitors-induced hypophysitis","volume":"181","author":"Albarel","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101411_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12026-016-8817-7","article-title":"HLA-DRB1 the notorious gene in the mosaic of autoimmunity","volume":"65","author":"Arango","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.beem.2020.101411_bib18","first-page":"517","article-title":"Hyperstimulation of adaptive immunity as the common pathway for silicone breast implants, autoimmunity, and lymphoma of the breast","volume":"21","author":"Watad","year":"2019","journal-title":"Isr Med Assoc J: IMAJ"},{"key":"10.1016\/j.beem.2020.101411_bib19","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/ije\/dyy217","article-title":"Silicone breast implants and the risk of autoimmune\/rheumatic disorders: a real-world analysis","volume":"47","author":"Watad","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.beem.2020.101411_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.beem.2020.101411_bib21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"10.1016\/j.beem.2020.101411_bib22","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2169\/internalmedicine.9518-17","article-title":"Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody","volume":"57","author":"Shiba","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2020.101411_bib23","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.2337\/dc15-1331","article-title":"Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2020.101411_bib24","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101411_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.beem.2020.101411_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2020.101411_bib27","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101411_bib28","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2020.101411_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-225048","article-title":"Delayed presentation of isolated adrenocorticotropin insufficiency after nivolumab therapy for advanced non-small-cell lung carcinoma (NSCLC)","volume":"2018","author":"Shrotriya","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.beem.2020.101411_bib30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.14740\/jocmr3257w","article-title":"Isolated adrenocorticotropic hormone deficiency and severe hypercalcemia after destructive thyroiditis in a patient on nivolumab therapy with a malignant melanoma","volume":"10","author":"Takebayashi","year":"2018","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.beem.2020.101411_bib31","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1111\/1346-8138.13571","article-title":"Isolated adrenocorticotropic hormone deficiency associated with nivolumab therapy","volume":"44","author":"Narahira","year":"2017","journal-title":"J Dermatol"},{"key":"10.1016\/j.beem.2020.101411_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF03347700","article-title":"Isolated adrenocorticotropic hormone deficiency due to probable lymphocytic hypophysitis in a man","volume":"17","author":"Escobar-Morreale","year":"1994","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.beem.2020.101411_bib33","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2169\/internalmedicine.8548-16","article-title":"Isolated adrenocorticotropic hormone deficiency caused by nivolumab in a patient with metastatic lung cancer","volume":"56","author":"Takaya","year":"2017","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2020.101411_bib34","doi-asserted-by":"crossref","first-page":"102454","DOI":"10.1016\/j.autrev.2019.102454","article-title":"Isolated autoimmune adrenocorticotropic hormone deficiency: from a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors","volume":"19","author":"Percik","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2020.101411_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101411_bib36","doi-asserted-by":"crossref","first-page":"1039 e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.beem.2020.101411_bib37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)","volume":"14","author":"Klein","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beem.2020.101411_bib38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/clin.1997.4412","article-title":"Epidemiology and estimated population burden of selected autoimmune diseases in the United States","volume":"84","author":"Jacobson","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.beem.2020.101411_bib39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101411_bib40","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2265.2008.03338.x","article-title":"The incidence of autoimmune thyroid disease: a systematic review of the literature","volume":"69","author":"McGrogan","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2020.101411_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226516","article-title":"Population-based estimates of humoral autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960\u20132014","volume":"15","author":"Dillon","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.beem.2020.101411_bib42","doi-asserted-by":"crossref","first-page":"101371","DOI":"10.1016\/j.beem.2019.101371","article-title":"Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation","author":"Gubbi","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2020.101411_bib43","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2020.101411_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beem.2020.101411_bib45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2337\/dc12-0421","article-title":"beta-cell mass and turnover in humans: effects of obesity and aging","volume":"36","author":"Saisho","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2020.101411_bib46","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.beem.2020.101411_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2020.101411_bib48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2020.101411_bib49","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1530\/EJE-13-0528","article-title":"Addison's disease: a survey on 633 patients in Padova","volume":"169","author":"Betterle","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2020.101411_bib50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000443872","article-title":"From appearance of adrenal autoantibodies to clinical symptoms of Addison's disease: natural history","volume":"46","author":"Betterle","year":"2016","journal-title":"Front Horm Res"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X20300385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:55:37Z","timestamp":1761497737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X20300385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1521690X20300385"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2020.101411","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2020.101411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101411"}}